NCT03347617 2025-09-09
Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma
OHSU Knight Cancer Institute
Phase 2 Terminated
Clinical Trials
9 trialsNCT01336803 2023-12-27
Osteosarcoma
Stanford University
Phase 2 Completed
NCT00659126 2023-09-07
Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT03325166 2022-08-10
Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00978562 2022-08-03
DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Completed
NCT00103038 2022-06-09
Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
OHSU Knight Cancer Institute
Phase NA Completed
NCT01815333 2020-10-19
Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging
M.D. Anderson Cancer Center
Phase NA Completed
NCT01927887 2017-06-06
Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study
Massachusetts General Hospital
Phase NA Completed
NCT00660543 2017-05-16
MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy
OHSU Knight Cancer Institute
Phase NA Completed